Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Froklage FE, Oosterbaan LJ, Sizoo EM, de Groot M, Bosma I, Sanchez E, Douw L, Heimans JJ, Reijneveld JC, Lagerwaard FJ, Buter J, Uitdehaag BM, Klein M, Postma TJ. Froklage FE, et al. Among authors: buter j. J Neurooncol. 2014 Jan;116(2):387-94. doi: 10.1007/s11060-013-1310-4. Epub 2013 Nov 22. J Neurooncol. 2014. PMID: 24264531
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Vos MJ, Berkhof J, Hoekstra OS, Bosma I, Sizoo EM, Heimans JJ, Reijneveld JC, Sanchez E, Lagerwaard FJ, Buter J, Noske DP, Postma TJ. Vos MJ, et al. Among authors: buter j. Neuroradiology. 2012 Jun;54(6):539-46. doi: 10.1007/s00234-011-0908-5. Epub 2011 Jul 14. Neuroradiology. 2012. PMID: 21755329 Clinical Trial.
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. Hoogstrate Y, et al. Among authors: buter j. Neuro Oncol. 2022 Mar 12;24(3):429-441. doi: 10.1093/neuonc/noab231. Neuro Oncol. 2022. PMID: 34608482 Free PMC article.
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M. Gahrmann R, et al. Among authors: buter j. Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311. Neuro Oncol. 2017. PMID: 28204639 Free PMC article. Clinical Trial.
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Taal W, et al. Among authors: buter j. Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035291 Clinical Trial.
The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.
Gahrmann R, Smits M, Vernhout RM, Taal W, Kapsas G, de Groot JC, Hanse M, Vos M, Beerepoot LV, Buter J, Flach ZH, van der Holt B, van den Bent M. Gahrmann R, et al. Among authors: buter j. Neurooncol Adv. 2022 Mar 9;4(1):vdac032. doi: 10.1093/noajnl/vdac032. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35419519 Free PMC article.
103 results